News & Views

Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Greece

News,

Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Greek EOF for the…

Telix Launches New Prostate Cancer Imaging Agent, Gozellix®, in U.S.

News,

Telix today announces that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is now commercially available nationally in the United…

Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Germany

News,

Telix today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Germany by BfArM[2] for the…

Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Portugal

News,

Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Portugal by INFARMED for the…

Telix Investor Day in New York City on June 11, 2025: Presenting KOLs

News,

Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan

News,

Telix Highlights ProstACT Global, CUPID and STARLITE Therapy Studies in Prostate and Kidney Cancer at ASCO Annual Meeting 2025

News,

Telix to Host Investor Day in New York City on June 11, 2025

News,

Telix at ANZSNM Annual Scientific Meeting 2025

ASX, News,

Telix Responds to Recent U.S. Government Actions- Most Favored Nation

News,

Telix advises that it has evaluated the Executive Order issued by the United States (U.S.) Government to implement a “Most-Favored Nation” (MFN) policy around drug pricing. Based on currently available…